Gilead targets MacroGenics in potential $1B+ DART deal
This article was originally published in Scrip
Executive Summary
Gilead Sciences is paying $30 million to MacroGenics for certain rights to its Dual-Affinity Re-Targeting (DART) technology, a bispecific antibody platform in which a single recombinant molecule is able to target two different antigens.